Company Encyclopedia
View More
name
CSL Limited
CSLLY.US
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments.
1.902 T
CSLLY.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking54/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE16.36%A
    • Profit Margin19.30%A
    • Gross Margin51.93%B
  • Growth ScoreC
    • Revenue YoY5.12%C
    • Net Profit YoY13.63%C
    • Total Assets YoY3.63%C
    • Net Assets YoY10.34%B
  • Cash ScoreC
    • Cash Flow Margin518.25%C
    • OCF YoY5.12%C
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreC
    • Gearing Ratio45.67%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jefferies sees CSL's China albumin hit as short-term; keeps PT unchanged

    Jefferies maintains a "buy" rating and A$237 price target for CSL Ltd despite China's cost containment measures affecting albumin demand. They expect a rebound in H2 FY26. Albumin penetration in Chinese hospitals is low, offering growth potential. 12 of 16 analysts rate CSL "buy" or higher. The stock has fallen 34.1% this year.

    Reuters·
    US
    CSLLY
    +2.28%
    Reuters·
    US
    CSLLY
    +2.28%

    CSL Ltd Sees High Single-Digit NPAT Growth Beyond FY26

    CSL Ltd :SEES MID SINGLE-DIGIT REVENUE GROWTH BEYOND FY26SEES HIGH SINGLE-DIGIT NPAT GROWTH BEYOND FY26SEES CONTINUED DIVIDENDS AND MULTI-YEAR, ON-MARKET SHARE BUYBACKS BEYOND FY26

    Reuters·
    US
    CSLLY
    +2.28%
    Reuters·
    US
    CSLLY
    +2.28%

    CSL Says CSL Seqirus & Vaccine Industrial Sign Landmark MoU With Ministry Of Health

    CSL Ltd :CSL SEQIRUS AND VACCINE INDUSTRIAL COMPANY SIGN LANDMARK MEMORANDUM OF UNDERSTANDING WITH MINISTRY OF HEALTHMOU TO LOCALIZE MANUFACTURING OF CELL-BASED SEASONAL AND PANDEMIC INFLUENZA VACCINES

    Reuters·
    US
    CSLLY
    +2.28%
    Reuters·
    US
    CSLLY
    +2.28%

    CSL Says No Longer Targeting Completion Of Demerger In FY2026

    CSL Ltd :FINANCIAL YEAR 2026 REVENUE GROWTH OUTLOOK TO 2-3%SEES FINANCIAL YEAR 2026 NPATA GROWTH 4-7%NO LONGER TARGETING COMPLETION OF A DEMERGER IN FINANCIAL YEAR 2026ADVANCING WITH PREVIOUSLY PROPOSED DEMERGER TIMING WILL NOT FULLY CAPTURE SEQIRUS' VALUE POTENTIAL

    Reuters·
    US
    CSL
    -0.95%
    US
    CSLLY
    +2.28%
    Reuters·
    US
    CSL
    -0.95%
    US
    CSLLY
    +2.28%

    CSL Ltd - Unit Signs LoI With Pan-Canadian Pharmaceutical Alliance For Hemgenix Reimbursement

    Oct 6 (Reuters) - CSL Ltd (CSL.AX) :* CSL LTD - UNIT SIGNS LOI WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR HEMGENIX REIMBURSEMENT* CSL LTD - LOI FOR PUBLIC REIMBURSEMENT OF HEMGENIX Source text: Further company coverage: (CSL.AX)

    Reuters·
    US
    CSLLY
    +2.28%
    Reuters·
    US
    CSLLY
    +2.28%
    © 2025 Longbridge｜Disclaimer